Mo. Elrggal
@kidneyman.bsky.social
๐ค 709
๐ฅ 1454
๐ 47
Nephrologist, ๐ช๐ฌ, Father, NSMC, NephJC, ISNACT, ISNGTF, NDTsocial, PLOSONE, ESNT, JHAH
reposted by
Mo. Elrggal
Swapnil Hiremath ๐๐จ๐ฆ
19 days ago
large cohort study of CDK 4/6 BRAF EGFR VEGF and other cancer treatments
#OncoNephrology
#NephSky
#KidneyWk
jamanetwork.com/journals/jam...
from Shuchi Anand et al from
@stanfordmedicine.bsky.social
1
6
6
reposted by
Mo. Elrggal
ASN Publications
18 days ago
Now live in #ASNJASN, simultaneously published with #KidneyWk: "Immunosuppression in Older Kidney Transplant Recipients: A Randomized Controlled Trial" Read more:
kidney.pub/JASN0924
1
6
6
reposted by
Mo. Elrggal
JAMA
18 days ago
Among more than 800 000 CKD-PC participants, discordance between cystatin C and creatinine eGFR values was associated with increased risk of death, cardiovascular events, and kidney failure. #KidneyWK @asnkidney.bsky.social
ja.ma/4oV4DtU
0
6
7
reposted by
Mo. Elrggal
American Journal of Kidney Diseases
18 days ago
In celebration of
#KidneyWk
, the entire November issue is FREE to access until November 30, 2025! Check out the plain-language summaries on what inspired each study, the basic approach taken, what was learned, and why it matters:
bit.ly/3X1XpZj
1
8
5
reposted by
Mo. Elrggal
Cristina Popa
3 months ago
Thoughtful and controversial blog from Last Month in Nephrology
#NephSky
#MedSy
Albuminuria as an ESKD surrogate may be a statistical mirage, limited by imprecision and overinterpretation However, it moved nephrology forward and made studies happen
lastmonthinnephrology.wordpress.com
loading . . .
Last Month in Nephrology
https://lastmonthinnephrology.wordpress.com/
1
11
4
reposted by
Mo. Elrggal
Nephrology Journal Club
3 months ago
๐ค How often is end-stage kidney disease in patients with MCD/ FSGS?
#NephSky
#MedSky
@brianrifkin.bsky.social
dissected the conclusions from the RaDar study in this
#NephJCshorts
*the original article from
@asnpublications.bsky.social
www.nephjc.com/news/nephjc-...
loading . . .
NephJC Shorts: MCD and FSGS Outcomes โ NephJC
A NephJC Shorts discussion of the long term data on kidney failure in FSGS and MCD
https://www.nephjc.com/news/nephjc-shorts-mcd-fsgs
2
8
8
reposted by
Mo. Elrggal
Nephrology Journal Club
4 months ago
On 7/22/25 at 9pm EST only on Bluesky!
#NephSky
#MedSky
join us for a lively discussion. We're debating eGFRdiff (the gap that is sometimes present between the eGFR of cystatin C and creatinine). What does it mean, what causes it and what you should do about it.
#NephJC
www.nephjc.com/news/egfrdiff
loading . . .
Mind The Gap: When eGFR Creatinine and Cystatin C Disagree โ NephJC
This week, we will discuss the clinical significance of eGFRdiff, the difference in eGFRcys (cystatin C) and eGFRcr (creatinine).
https://www.nephjc.com/news/egfrdiff
0
37
23
Read this piece from the ERAKI working group at the
@ndt-era.bsky.social
regarding the results of the DEFENDER trial published last August
@jama.com
academic.oup.com/ndt/article/...
4 months ago
0
2
1
reposted by
Mo. Elrggal
Swapnil Hiremath ๐๐จ๐ฆ
5 months ago
We donโt get to discuss every important study that comes out on
#NephJC
Hence
#NephJCShorts
www.nephjc.com/news/nephjc-...
loading . . .
Introducing NephJC Shorts โ NephJC
In just over a decade of critical appraisal on NephJC, we have done several experiments. Some of them have worked out phenomenally well, such as the Freely Filtered podcast. Others were not ready for ...
https://www.nephjc.com/news/nephjc-shorts
1
15
9
reposted by
Mo. Elrggal
ISNkidneycare
5 months ago
Enjoy the latest edition of ISN-ACT Global Trials Focus (GTF), a monthly list identifying and summarizing recent interesting trials relevant to kidney disease. Each trial is reviewed in context and assessed for its risk of bias in key areas โก
http://lite.spr.ly/6...
loading . . .
Clinical Trials (ISN-ACT) - International Society of Nephrology
The ISN-Advancing Clinical Trials (ISN-ACT) is an ISN initiative to encourage existing infrastructures within ISN to improve the global nephrology communityโs participation in clinical trial research.
http://lite.spr.ly/6003yaGP
1
1
2
reposted by
Mo. Elrggal
American Journal of Kidney Diseases
5 months ago
On the
#AJKDBlog
, catch up on these interviews with: - Oshozimhede E. Iyalomhe on statin use in CKD - Roger Rodby and William Whittier about renal tubular acidoses - Subhash Chander on urea as a tool for managing SIADH-induced hyponatremia
bit.ly/3ztk4VV
(FREE)
0
7
3
reposted by
Mo. Elrggal
UW Nephrology
7 months ago
Dr. Katherine Tuttle focuses her educational Grand Rounds talk on a reemerging topic: "New Approaches to Blocking
#Aldosterone
&
#Angiotensinogen
for
#Hypertension
or
#CKD
."
#kidney
#nephrology
#nephsky
@uwmedicine.bsky.social
youtu.be/TeWkmCopuzk
loading . . .
Kathy Tuttle, MD - New Approaches to Blocking Aldosterone & Angiotensinogen for Hypertension or CKD
YouTube video by University of Washington Division of Nephrology
https://youtu.be/TeWkmCopuzk
0
8
3
reposted by
Mo. Elrggal
Swapnil Hiremath ๐๐จ๐ฆ
7 months ago
When
@rajmehrotra.bsky.social
is giving a talk on the factors for home dialysis stagnation and growth in US at the
#CSNAGM
We get to see a CJASN abstract! From Divya Bajpai
0
12
1
reposted by
Mo. Elrggal
American Society of Diagnostic and Interventional Nephrology
7 months ago
๐ฃ Reminder! ASDIN is accepting applications for the $25K Research Grant in Vascular Access โ but donโt wait! ๐ Applications close July 15, 2025. Click here to learn more:
www.asdin.org/news/699844/...
#vascularaccess
#ASDIN
#researchgrant
#nephrology
0
1
1
reposted by
Mo. Elrggal
Edgar V. Lerma ๐ต๐ญ
7 months ago
Use of SGLT2 inhibitors (SGLT2i) in ADPKD is not "presently" recommended, because people with ADPKD have been excluded from the clinical trials; thus, its safety has not been evaluated (from
@kdigo.org
)
#Nephpearls
#NephSky
๐
kdigo.org/guidelines/a...
0
5
2
reposted by
Mo. Elrggal
Podocyte Talk - Dr. Anass Qasem
7 months ago
Finerenone reduced kidney and cardiovascular events in CKD and T2D patients, regardless of frailty. Benefits included lower albuminuria and slower eGFR decline, supporting its use even in frail individuals.
#podocytetalk
#Nephpearls
#Nephrology
#CKD
journals.lww.com/cjasn/abstra...
0
2
1
reposted by
Mo. Elrggal
Nephrology Times
7 months ago
Sparsentan is now approved for the treatment of IgAN in European Union countries.
#igan
#iganephropathy
#kidneydisease
#nephrology
#nephsky
www.docwirenews.com/post/eu-appr...
loading . . .
EU Approves Sparsentan for Treatment of IgAN | Docwire News
The European Commission has granted standard approval to sparsentan for the treatment of adults with primary IgA nephropathy (IgAN).
https://www.docwirenews.com/post/eu-approves-sparsentan-for-treatment-of-igan
0
9
4
reposted by
Mo. Elrggal
International Society of Renal Nutrition and Metabolism
7 months ago
SGLT2 Inhibitors and Risk for Hyperkalemia Among Individuals Receiving RAAS Inhibitors
jamanetwork.com/journals/jam...
loading . . .
SGLT2 Inhibitors and Risk for Hyperkalemia Among Individuals Receiving RAAS Inhibitors
This cohort study evaluates the association between sodium-glucose cotransporter 2 inhibitors and hyperkalemia in individuals with diabetes, heart failure, or chronic kidney disease receiving renin-an...
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2833308
0
4
1
reposted by
Mo. Elrggal
Edgar V. Lerma ๐ต๐ญ
7 months ago
Do you prescribe SGLT2 inhibitors (SGLT2i) for patients with ADPKD?
#Nephpearls
#AskRenal
#NephSky
โค๏ธ LIKE for YES (and why?) โ X for NO (and why?) ๐
pubmed.ncbi.nlm.nih.gov/39099568/
4
8
3
Do you allow hemodialysis patients with permanent HD catheters to shower? Yes No Other, please state
www.ajkd.org/article/S027...
#nephinp
#nephrology_in_practice
@ajkd.bsky.social
loading . . .
Patient and Health Care Provider Perspectives on Showering for Patients With Hemodialysis Central Venous Catheters: A Survey Study
Patients on hemodialysis using a central venous catheter (CVC) are often advised not to shower due to infection risk. This study assessed practices and attitudes of patients and health care providers ...
https://www.ajkd.org/article/S0272-6386(25)00008-3/fulltext
7 months ago
0
1
0
reposted by
Mo. Elrggal
Kidney International
7 months ago
Progress, challenges, and pragmatic concessions in predicting relative risk of kidney survival in ARPKD
doi.org/10.1016/j.kint.2025.02.018
Original article:
doi.org/10.1016/j.kint.2025.01.023
#KICommentary
#MedSky
#NephSky
#polycystickidneydisease
0
3
3
reposted by
Mo. Elrggal
Maddalena Marasร
7 months ago
Alternative complement pathway dysregulation in CKD and CKD progression, endothelial inflammation and cardiovascular outcomesโฆ room for complement inhibitors beyond complement-mediated kidney diseases?
www.jci.org/articles/vie...
#NephSky
#MedSky
add a skeleton here at some point
0
3
1
reposted by
Mo. Elrggal
American Journal of Kidney Diseases
7 months ago
Editorial by Harshil A. Fichadiya and John C. Lieske: Do Topiramate and Zonisamide Cause Kidney Stones?
bit.ly/FichadiyaED25
(FREE)
0
2
1
reposted by
Mo. Elrggal
Kidney International
7 months ago
#KIControversies
in Nephrology Clinical utility of donor-derived cell-free DNA ๐งฌtesting for kidney transplant monitoring in selected patients You can read the โ Point โ Counterpoint โ Editor's summary in the May issue of KI
doi.org/10.1016/j.kint.2025.01.039
#MedSky
#NephSky
#kidneytransplant
0
10
5
When to use spironolactone, eplerenone or finerenone in the spectrum of cardiorenal diseases
academic.oup.com/ndt/article/...
An amazing article from the high impact articles published by
@ndt-era.bsky.social
loading . . .
When to use spironolactone, eplerenone or finerenone in the spectrum of cardiorenal diseases
ABSTRACT. Kidney disease frequently coexists with cardiovascular (CV) diseases, and this dual presence significantly amplifies the risk of adverse clinical
https://academic.oup.com/ndt/article/39/7/1063/7513181
7 months ago
0
2
0
reposted by
Mo. Elrggal
American Journal of Kidney Diseases
7 months ago
Stopping Versus Continuing Metformin in Patients With Advanced CKD: A Nationwide Scottish Target Trial Emulation Study
bit.ly/3ZdrYxb
#OpenAccess
#VisualAbstract
#CKD
0
7
2
#nephsky
add a skeleton here at some point
8 months ago
0
0
0
Despite my ranking, I am still getting both winners at the finals..
@nephmadness.bsky.social
8 months ago
0
0
1
reposted by
Mo. Elrggal
Swapnil Hiremath ๐๐จ๐ฆ
8 months ago
And I did that in 2016 in response to Dr Rodbyโs decisions Funnily, today he agrees with me over on Xitter that this was a giant
#BlueRibbonFail
#NephMadness
1
5
3
reposted by
Mo. Elrggal
Swapnil Hiremath ๐๐จ๐ฆ
8 months ago
What is the impact of retracted studies being cited in systematic reviews? Cool study in
@jama.com
IM
jamanetwork.com/journals/jam...
Even cooler: โfeet of clayโ detector from
@gcabanac.cpesr.fr
used here
dbrech.irit.fr/pls/apex/f?p...
#MedSky
#EpiSky
loading . . .
Inclusion of Retracted Studies in Systematic Reviews and Meta-Analyses of Interventions
This systematic review and meta-analysis identifies reports of systematic reviews that included retracted studies in their meta-analyses, and assesses the impact of these retracted studies on the resu...
https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2831911
2
23
9
reposted by
Mo. Elrggal
ASN Publications
8 months ago
The April issue of JASN is now available online! Topics covered this month include: - Novel Therapies for IgA Nephropathy - Rituximab in Podocytopathies - and more Find the issue here:
journals.lww.com/jas...
#ASNJASN
0
8
6
Results of the first round are up
@nephmadness.bsky.social
#nephsky
Excellent results for
@nephsim.bsky.social
8/8
8 months ago
1
13
6
Check my latest editorial @kidney360
journals.lww.com/kidney360/fu...
8 months ago
0
2
0
reposted by
Mo. Elrggal
Edgar V. Lerma ๐ต๐ญ
8 months ago
What other Landmark Trials in ADPKD should be included in this listโ๏ธ
#Nephpearls
#NephJC
#NephSky
โน๏ธ CRISP
pubmed.ncbi.nlm.nih.gov/16707749/
โน๏ธ Everolimus
pubmed.ncbi.nlm.nih.gov/20581392/
โน๏ธ TEMPO 3:4
pubmed.ncbi.nlm.nih.gov/23121377/
โน๏ธ HALT A
pubmed.ncbi.nlm.nih.gov/25399733/
โน๏ธ HALT B โน๏ธ REPRISE
1
7
3
reposted by
Mo. Elrggal
ASN Publications
8 months ago
The ASN Journal Portfolio seeks early career scientists and junior faculty members interested in participating in the editorial process of peer reviewed journals to join our Junior Associate Editor (JAE) Program. Learn more and apply by May 2.
bit.ly/TraineePrograms
@rajmehrotra.bsky.social
0
1
2
reposted by
Mo. Elrggal
Nephrology Times
8 months ago
Trials of
#SGLT2
inhibitors dapagliflozin and empagliflozin have shown renal benefits, but those trials excluded patients with
#ADPKD
.
#nephrology
#nephsky
#kidneydisease
loading . . .
Dapagliflozin With Tolvaptan May Have Additive Effect in Slowing ADPKD Progression | Docwire News
A study examined the effects of adding dapagliflozin to treatment with tolvaptan in patients with autosomal dominant polycystic kidney disease (ADPKD).
https://www.docwirenews.com/post/dapagliflozin-with-tolvaptan-may-have-additive-effect-in-slowing-adpkd-progression
0
3
2
reposted by
Mo. Elrggal
KDIGO
8 months ago
The draft Scope of Work for the KDIGO 2025 B CellโMediated Therapies Controversies Conference is open for public comment through April 21. Download the SOW and submit feedback via the form on the conference site:
kdigo.org/conferences/...
#BCell
1
3
1
reposted by
Mo. Elrggal
Nephrology Times
8 months ago
โ ๏ธ The FDA has approved oral iptacopan to treat proteinuria in adults with C3 glomerulopathy. This is the first FDA-approved treatment for C3G.
#fda
#c3glomerulopathy
#c3g
#kidneydisease
#nephrology
#nephsky
loading . . .
Iptacopan Becomes First Approved Therapy for C3G | Docwire News
Oral iptacopan (Fabhalta) has become the first FDA-approved treatment for proteinuria in adults with C3 glomerulopathy (C3G).
https://www.docwirenews.com/post/iptacopan-becomes-first-approved-therapy-for-c3g
0
5
4
reposted by
Mo. Elrggal
Nephrology Journal Club
8 months ago
Happening this week! The
@kdigo.org
guidelines in
#ADPKD
#PKD
on
#NephJC
www.nephjc.com/news/adpkd-k...
Summary from
@brianrifkin.bsky.social
loading . . .
KDIGO 2025 ADPKD Guidelines Review โ NephJC
This week, we will discuss the first iteration of KDIGOโs 2025 guidelines on ADPKD. These guidelines are a result of a decade of global collaboration between physicians, researchers, advocates, ...
https://www.nephjc.com/news/adpkd-kdigo2025
0
24
12
A new trial published
@ndt-era.bsky.social
assessing a new device integrated in the PD cycler for remote monitoring of automated PD, whether it will improve clinical outcomes or not.
8 months ago
0
2
0
#nephsky
add a skeleton here at some point
8 months ago
0
1
0
#nephsky
add a skeleton here at some point
8 months ago
0
2
0
#nephsky
add a skeleton here at some point
8 months ago
0
1
0
Still anyone thinking
#denervation
will do better than
#noveantiHTNmedications
?! in the first round of
@nephmadness.bsky.social
#trashtalks
#nephmadness
#Noveltreatments
FTW!
8 months ago
1
1
1
I am "CONVINCE"D that
#hemodiafiltration
will overcome
#incrementalhemodialysis
in the
@nephmadness.bsky.social
match on the first round. you will be lost if you chose
#incrementalHD
#trashtalk
#nephmadness
or may be the
#blueribbonfail
are not yet "CONVINVE"D !!
8 months ago
1
3
2
reposted by
Mo. Elrggal
Amy Wieckowski
8 months ago
Thanks for the tip off
@robertbrownpharm.bsky.social
- sharing for any others who might find this useful
#pharmsky
#nephsky
#medsky
add a skeleton here at some point
0
4
1
reposted by
Mo. Elrggal
Swapnil Hiremath ๐๐จ๐ฆ
8 months ago
we have reached the point where we seriously should avoid travelling to the US Sorry
@asnkidney.bsky.social
@ahascience.bsky.social
@kidneycon.bsky.social
#NephSky
0
10
3
reposted by
Mo. Elrggal
Swapnil Hiremath ๐๐จ๐ฆ
8 months ago
Nice blurb in
@asnkidney.bsky.social
in the loop about the CRRT curriculum in
@ajkd.bsky.social
Free link (few more weeks, download now)
authors.elsevier.com/sd/article/S...
Thanks to
@nephcrit.bsky.social
& Ted Clark for helming this &
@melhoenig.bsky.social
for the invite!
#NephSky
#Free
1
16
9
reposted by
Mo. Elrggal
NDT
8 months ago
Combination therapy: an upcoming paradigm to improve kidney and cardiovascular outcomes in chronic kidney disease ๐
doi.org/10.1093/ndt/...
loading . . .
Combination therapy: an upcoming paradigm to improve kidney and cardiovascular outcomes in chronic kidney disease
PLAIN ENGLISH SUMMARYโ. In this article the authors review recent advances in the treatment of chronic kidney disease (CKD) with diabetes, and summarize ev
https://doi.org/10.1093/ndt/gfae212
0
4
3
Load more
feeds!
log in